Antibacterial Porous Systems Based on Polylactide Loaded with Amikacin

Abstract

Three porous matrices based on poly(lactic acid) are proposed herein for the controlled release of amikacin. The materials were fabricated by the method of spraying a surface liquid. Description is given as to the possibility of employing a modifier, such as a silica nanocarrier, for prolonging the release of amikacin, in addition to using chitosan to improve the properties of the materials, e.g., stability and sorption capacity. Depending on their actual composition, the materials exhibited varied efficacy for drug loading, as follows: 25.4 ± 2.2 μg/mg (matrices with 0.05% w/v of chitosan), 93 ± 13 μg/mg (with 0.08% w/v SiO2 amikacin modified nanoparticles), and 96 ± 34 μg/mg (matrices without functional additives). An in vitro study confirmed extended release of the drug (amikacin, over 60 days), carried out in accordance with the mathematical Kosmyer–Pepas model for all the materials tested. The matrices were also evaluated for their effectiveness in inhibiting the growth of bacteria such as Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Concurrent research was conducted on the transdermal absorption, morphology, elemental composition, and thermogravimetric properties of the released drug.

Formulation and Evaluation of Amikacin Sulfate Loaded Dextran Nanoparticles against Human Pathogenic Bacteria

“…Another study showed that 25% amikacin sulfate could be entrapped in thiolated chitosan nanoparticles for oral delivery, and drug release was determined in 18 h [20]. Recently, polylactide matrices loaded with amikacin sulfate were able to release the amikacin over 60 days [21]. On the other hand, according to these findings of their investigation, the current study released amikacin release much uniformly that, reached 37% release in 7 h, which will be more significant to optimize the dosage to once daily because the dosage frequencies vary with pathological effects.…”